Clinical trial
A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of BGM0504 Versus Placebo in Patients with Type 2 Diabetes, Inadequately Controlled with Diet and Exercise Alone
NCT06716203 is registered in ClinicalTrials.gov with BrightGene Bio-Medical Technology Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of BGM0504 Versus Placebo in Patients with Type 2 Diabetes, Inadequately Controlled with Diet and Exercise Alone
- Lead sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 2, 2024
- Completion date
- August 25, 2026
- Enrollment
- 207 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
type 2 diabetes mellitus (t2dm)